{"id":1094,"date":"2025-07-31T06:00:56","date_gmt":"2025-07-31T06:00:56","guid":{"rendered":"https:\/\/perfusfind.com\/ic\/?p=1094"},"modified":"2025-07-31T00:42:47","modified_gmt":"2025-07-31T00:42:47","slug":"prognostic-implication-of-venoarterial-extracorporeal-membrane-oxygenation-in-acute-myocardial-infarction-related-cardiogenic-shock","status":"publish","type":"post","link":"https:\/\/perfusfind.com\/ic\/index.php\/2025\/07\/31\/prognostic-implication-of-venoarterial-extracorporeal-membrane-oxygenation-in-acute-myocardial-infarction-related-cardiogenic-shock\/","title":{"rendered":"Prognostic implication of venoarterial extracorporeal membrane oxygenation in acute myocardial infarction-related cardiogenic shock"},"content":{"rendered":"
\n

Summary <\/strong><\/p>\n<\/blockquote>\n

This retrospective study aimed to evaluate clinical outcomes in patients receiving veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock (CS), comparing acute myocardial infarction-related cardiogenic shock (AMI-CS) with non-AMI-CS. Analysis of data from 667 patients treated between 2008 and 2023 showed that AMI-CS was associated with significantly lower in-hospital mortality compared to non-AMI-CS. Independent predictors of favorable outcomes included younger age, shorter duration of cardiac arrest, absence of severe left ventricular dysfunction, lack of renal replacement therapy, higher hemoglobin and arterial pH levels, and lower lactate levels. The findings underscore VA-ECMO’s role in improving outcomes particularly in AMI-CS patients.<\/p>\n

\n
\n
\n
\n
Minimize image<\/div>\n
Edit image<\/div>\n
Delete image<\/div>\n<\/div>\n<\/div>\n

\"\"<\/div>